ES2708807T3 - Biomarcadores de la lipogénesis de novo y métodos que los emplean - Google Patents
Biomarcadores de la lipogénesis de novo y métodos que los emplean Download PDFInfo
- Publication number
- ES2708807T3 ES2708807T3 ES14870759T ES14870759T ES2708807T3 ES 2708807 T3 ES2708807 T3 ES 2708807T3 ES 14870759 T ES14870759 T ES 14870759T ES 14870759 T ES14870759 T ES 14870759T ES 2708807 T3 ES2708807 T3 ES 2708807T3
- Authority
- ES
- Spain
- Prior art keywords
- dnl
- level
- biomarkers
- total
- index
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 236
- 238000000034 method Methods 0.000 title claims abstract description 108
- 230000004132 lipogenesis Effects 0.000 title claims abstract description 67
- 239000000523 sample Substances 0.000 claims abstract description 74
- 150000002632 lipids Chemical class 0.000 claims abstract description 45
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract description 34
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract description 34
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940031439 squalene Drugs 0.000 claims abstract description 34
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000012472 biological sample Substances 0.000 claims abstract description 33
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims abstract description 8
- 239000012491 analyte Substances 0.000 claims abstract description 3
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 claims abstract 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 claims abstract 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims abstract 5
- 229940049918 linoleate Drugs 0.000 claims abstract 5
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims abstract 4
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 claims abstract 4
- 229940114079 arachidonic acid Drugs 0.000 claims abstract 2
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 140
- 201000010099 disease Diseases 0.000 claims description 94
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 73
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 71
- 239000000194 fatty acid Substances 0.000 claims description 71
- 229930195729 fatty acid Natural products 0.000 claims description 71
- 150000004665 fatty acids Chemical class 0.000 claims description 70
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 68
- 206010012601 diabetes mellitus Diseases 0.000 claims description 46
- 206010022489 Insulin Resistance Diseases 0.000 claims description 21
- 210000003491 skin Anatomy 0.000 claims description 20
- 150000003626 triacylglycerols Chemical class 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 16
- 210000002374 sebum Anatomy 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 abstract description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 abstract 2
- 235000021360 Myristic acid Nutrition 0.000 abstract 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 description 45
- 238000011282 treatment Methods 0.000 description 42
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 22
- 208000024172 Cardiovascular disease Diseases 0.000 description 21
- 208000008589 Obesity Diseases 0.000 description 21
- 235000020824 obesity Nutrition 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 18
- 206010019708 Hepatic steatosis Diseases 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 17
- 108090001061 Insulin Proteins 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 17
- 229940125396 insulin Drugs 0.000 description 17
- 208000020489 acute insulin response Diseases 0.000 description 16
- 238000003745 diagnosis Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 208000017520 skin disease Diseases 0.000 description 14
- 150000003904 phospholipids Chemical class 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 238000013178 mathematical model Methods 0.000 description 10
- 230000007863 steatosis Effects 0.000 description 10
- 231100000240 steatosis hepatitis Toxicity 0.000 description 10
- 239000003760 tallow Substances 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 9
- 229940067631 phospholipid Drugs 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 8
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 235000021588 free fatty acids Nutrition 0.000 description 7
- 201000009104 prediabetes syndrome Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000001280 Prediabetic State Diseases 0.000 description 6
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 150000008105 phosphatidylcholines Chemical class 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 238000013179 statistical model Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 4
- 101100528972 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPD3 gene Proteins 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 150000001840 cholesterol esters Chemical class 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- -1 for example Substances 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical class CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 208000032236 Predisposition to disease Diseases 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000003965 capillary gas chromatography Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000006442 Gastroschisis Diseases 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
- 208000030390 pulmonic stenosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 108010002139 very low density lipoprotein triglyceride Proteins 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
- G01N2800/7085—Lipogenesis or lipolysis, e.g. fatty acid metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918866P | 2013-12-20 | 2013-12-20 | |
| US201461934033P | 2014-01-31 | 2014-01-31 | |
| PCT/US2014/071035 WO2015095451A1 (en) | 2013-12-20 | 2014-12-18 | Biomakers of de novo lipogenesis and methods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2708807T3 true ES2708807T3 (es) | 2019-04-11 |
Family
ID=53403674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14870759T Active ES2708807T3 (es) | 2013-12-20 | 2014-12-18 | Biomarcadores de la lipogénesis de novo y métodos que los emplean |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160356798A1 (enExample) |
| EP (1) | EP3082833B1 (enExample) |
| JP (1) | JP6557235B2 (enExample) |
| AU (1) | AU2014364539B2 (enExample) |
| CA (1) | CA2933571A1 (enExample) |
| ES (1) | ES2708807T3 (enExample) |
| MX (1) | MX2016008045A (enExample) |
| SG (1) | SG11201604702YA (enExample) |
| WO (1) | WO2015095451A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105400732A (zh) * | 2015-11-19 | 2016-03-16 | 南京理工大学 | 一种酒精性脂肪肝斑马鱼模型的构建方法 |
| JP6992057B2 (ja) | 2016-06-10 | 2022-01-13 | クラリティ コスメティックス インコーポレイテッド | 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法 |
| GB201614455D0 (en) * | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| US11709169B2 (en) * | 2017-02-07 | 2023-07-25 | National Jewish Health | Lipid abnormalities and association with atopic allergic diseases |
| US20200033360A1 (en) * | 2017-03-31 | 2020-01-30 | Metabolon, Inc. | Comprehensive and quantitative lipid and tocopherol analysis |
| US11642300B2 (en) | 2019-05-15 | 2023-05-09 | Johnson & Johnson Consumer Inc. | Method of selecting skin treatment regimens, ingredients and compositions |
| US20220142560A1 (en) | 2020-11-06 | 2022-05-12 | Johnson & Johnson Consumer Inc. | Microbiome and metobolome clusters to evaluate skin health |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2459508A1 (en) * | 2001-09-24 | 2003-04-03 | Lipomics Technologies, Inc. | Methods of using quantitative lipid metabolome data |
| EP1739431A4 (en) * | 2004-04-23 | 2008-10-15 | Ajinomoto Kk | METHOD FOR ASSESSING NON-ALCOHOLIC STEATOHEPATITIS |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| EP2891885A3 (en) * | 2007-04-18 | 2015-10-14 | Health Diagnostic Laboratory, Inc. | Diabetes-related biomarkers and methods of use thereof |
| WO2010028336A2 (en) * | 2008-09-08 | 2010-03-11 | President And Fellows Of Harvard College | Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status |
| WO2012040318A2 (en) * | 2010-09-23 | 2012-03-29 | University Of Miami | Compositions, methods and kits for detecting melanoma and margins of melanoma |
-
2014
- 2014-12-18 AU AU2014364539A patent/AU2014364539B2/en active Active
- 2014-12-18 JP JP2016541152A patent/JP6557235B2/ja active Active
- 2014-12-18 US US15/104,560 patent/US20160356798A1/en not_active Abandoned
- 2014-12-18 WO PCT/US2014/071035 patent/WO2015095451A1/en not_active Ceased
- 2014-12-18 SG SG11201604702YA patent/SG11201604702YA/en unknown
- 2014-12-18 EP EP14870759.9A patent/EP3082833B1/en active Active
- 2014-12-18 ES ES14870759T patent/ES2708807T3/es active Active
- 2014-12-18 CA CA2933571A patent/CA2933571A1/en not_active Abandoned
- 2014-12-18 MX MX2016008045A patent/MX2016008045A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3082833A1 (en) | 2016-10-26 |
| AU2014364539A1 (en) | 2016-06-16 |
| WO2015095451A1 (en) | 2015-06-25 |
| US20160356798A1 (en) | 2016-12-08 |
| AU2014364539B2 (en) | 2019-08-01 |
| MX2016008045A (es) | 2016-10-12 |
| CA2933571A1 (en) | 2015-06-25 |
| SG11201604702YA (en) | 2016-07-28 |
| JP2017500567A (ja) | 2017-01-05 |
| EP3082833A4 (en) | 2017-08-09 |
| JP6557235B2 (ja) | 2019-08-07 |
| EP3082833B1 (en) | 2018-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2708807T3 (es) | Biomarcadores de la lipogénesis de novo y métodos que los emplean | |
| Fernández-Macías et al. | Atherogenic index of plasma: novel predictive biomarker for cardiovascular illnesses | |
| ES2443540T3 (es) | Biomarcadores para pre-diabetes y métodos que usan los mismos | |
| JP5363984B2 (ja) | 代謝年齢に関するバイオマーカー及びその使用方法 | |
| ES2669620T3 (es) | Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan | |
| Kim et al. | Comparison of epicardial, abdominal and regional fat compartments in response to weight loss | |
| JP2010507075A5 (enExample) | ||
| Ordak et al. | Ionized magnesium in plasma and erythrocytes for the assessment of low magnesium status in alcohol dependent patients | |
| Vela et al. | Pathophysiology and biomarker potential of fatty acid ethyl ester elevation during alcoholic pancreatitis | |
| Ogawa et al. | Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis | |
| Syed-Abdul et al. | Isotope labeling and biochemical assessment of liver-triacylglycerol in patients with different levels of histologically-graded liver disease | |
| Yan et al. | WY14643 improves left ventricular myocardial mitochondrial and systolic functions in obese rats under chronic persistent hypoxia via the PPARα pathway | |
| Huang et al. | Peroxisomal gene and protein expression increase in response to a high-lipid challenge in human skeletal muscle | |
| Perna et al. | Predicting visceral adipose tissue in older adults: A pilot clinical study | |
| Tokuda et al. | N epsilon-(hexanoyl) lysine, a new oxidative stress marker, is increased in metabolic syndrome, but not in obstructive sleep apnea | |
| Marasca et al. | Homocysteine plasma levels in patients affected by hidradenitis suppurativa: an Italian experience | |
| US20250362315A1 (en) | Quantification of lipoprotein subfraction by ion mobility | |
| WO2016100549A2 (en) | Ceramides for evaluating risk of cardiovascular disease | |
| Vaidya et al. | Skin tissue cholesterol assay correlates with presence of coronary calcium | |
| Freeman et al. | Dogs with diet-associated dilated cardiomyopathy have higher urine di-docosahexaenoyl (22: 6)-bis (monoacylglycerol) phosphate, a biomarker of phospholipidosis | |
| Wisniewski et al. | Bie nkowski | |
| HK1224920B (en) | Biomarkers of de novo lipogenesis and methods using the same | |
| HK1224920A1 (en) | Biomarkers of de novo lipogenesis and methods using the same | |
| Satoh et al. | Age-related alteration of the involvement of CD36 for salivary secretion from the parotid gland in mice | |
| RU2388413C1 (ru) | Способ оценки степени тяжести трофологической недостаточности у больных хронической обструктивной болезнью легких |